Morbidity and mortality rates in patients with active acromegaly are higher than the general population. Adequate biochemical control restores mortality to normal rates. Now, medical therapy has an increasingly important role in the treatment of patients with acromegaly. Somatostatin receptor ligands (SRLs) are considered the standard medical therapy, either after surgery or as a first-line therapy when surgery is deemed ineffective or is contraindicated.
The current article highlights the potential role of one such Somatostatin analogue– Pasireotide. Acromegaly is an insidious neuroendocrine disorder caused by hypersecretion of growth hormone (GH) by a somatotroph adenoma.Treatment modalities like surgery, radiation therapy were recommended for first-line use. Until recently the long-acting formulations of intramuscular octreotide and lanreotide were the only Somatostatin approved…
